
U.S. FDA Approves Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who are born during or entering their first RSV season. ENFLONSIA is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct, rapid and durable protection through 5 months, a typical RSV season, with the same 105 mg dose regardless of weight. A typical RSV season usually spans autumn to spring of the next year.
'RSV disease is the leading cause of infant hospitalization in the U.S. and can lead to serious respiratory conditions like bronchiolitis and pneumonia,' said Dr. Octavio Ramilo, chair of the Department of Infectious Diseases at St. Jude Children's Research Hospital and investigator for the CLEVER (MK-1654-004) and SMART (MK-1654-007) trials. 'ENFLONSIA combines dosing convenience with strong clinical data showing significant reductions in RSV disease incidence and hospitalizations, making it a promising new intervention to help protect infants from RSV.'
ENFLONSIA should not be administered to infants with a history of serious hypersensitivity reactions, including anaphylaxis, to any component of ENFLONSIA. See additional Selected Safety Information below.
The approval is based on results from the pivotal Phase 2b/3 CLEVER trial (MK-1654-004) evaluating a single dose of ENFLONSIA administered to preterm and full-term infants (birth to 1 year of age). The trial met its primary and key secondary endpoints, as outlined below.
ENFLONSIA demonstrated a reduction in incidence of RSV-associated medically attended lower respiratory infections (MALRI) requiring ≥1 indicator of lower respiratory infection (LRI) or severity compared to placebo through 5 months (primary endpoint) by 60.5% (95% CI: 44.2, 72.0, p<0.001) (incidence rates: ENFLONSIA, 0.026; placebo, 0.065).
ENFLONSIA demonstrated a reduction in RSV-associated hospitalizations through 5 months (key secondary endpoint) by 84.3% (95% CI: 66.7, 92.6, p<0.001) (incidence rates: ENFLONSIA, 0.004; placebo, 0.024), showing increasing efficacy with increasing disease severity.
The approval is also supported by results from the Phase 3 SMART trial (MK-1654-007) evaluating the safety and efficacy of ENFLONSIA versus palivizumab in infants at increased risk for severe RSV disease.
'ENFLONSIA provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season with the same dose regardless of weight,' said Dr. Dean Y. Li, president, Merck Research Laboratories. 'We are committed to ensuring availability of ENFLONSIA in the U.S. before the start of the upcoming RSV season to help reduce the significant burden of this widespread seasonal infection on families and health care systems.'
The U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices is expected to meet later this month to discuss and make recommendations for the use of ENFLONSIA in infants. Ordering is anticipated to begin in July, with shipments delivered before the start of the 2025-2026 RSV season.
About ENFLONSIA™ (clesrovimab-cfor)
ENFLONSIA (clesrovimab-cfor) is Merck's extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants who are born during or entering their first RSV season. ENFLONSIA is administered using non-weight-based dosing and is designed to provide direct, rapid and durable protection through 5 months, a typical RSV season. For infants born during the RSV season, ENFLONSIA is to be administered starting from birth. For infants born outside of the RSV season, ENFLONSIA should be administered prior to the start of their first RSV season. For infants undergoing cardiac surgery with cardiopulmonary bypass during or entering their first RSV season, an additional 105 mg dose is recommended as soon as the infant is stable after surgery.
Selected Safety Information for ENFLONSIA (clesrovimab-cfor)
Do not administer ENFLONSIA to infants with a history of serious hypersensitivity reactions, including anaphylaxis, to any component of ENFLONSIA.
Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.
The most common adverse reactions were injection-site erythema (3.8%), injection-site swelling (2.7%) and rash (2.3%).
About Clinical Trials and Data Supporting U.S. FDA Approval
The CLEVER trial (MK-1654-004) (NCT04767373) was a Phase 2b/3, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of ENFLONSIA in early and moderate preterm infants (≥29 to <35 weeks gestational age [GA]) and late preterm and full-term infants (≥35 weeks GA) entering their first RSV season. Participants were randomized 2:1 to receive a single 105 mg dose of ENFLONSIA (N=2,411) or saline placebo (N=1,203) by intramuscular (IM) injection.
The primary endpoint was the incidence of participants with RSV-associated medically attended lower respiratory infection (MALRI) characterized as cough or difficulty breathing and requiring ≥1 indicator of LRI (wheezing, rales/crackles) or severity (chest wall in-drawing/retractions, hypoxemia, tachypnea, dehydration due to respiratory symptoms) from Day 1 through Day 150 (5 months) after dosing. Medically attended includes all health care provider visits in settings such as outpatient clinic, clinical study site, emergency department, urgent care center and/or hospital. The key secondary endpoint was RSV-associated hospitalization through Day 150 (5 months).
The trial demonstrated that the safety profile of ENFLONSIA in infants entering their first RSV season was generally comparable to placebo. The most common adverse reactions were injection-site erythema occurring within 5 days post-dose (ENFLONSIA: 3.8%; placebo: 3.3%), injection-site swelling occurring within 5 days post-dose (ENFLONSIA: 2.7%; placebo: 2.6%) and rash occurring within 14 days post-dose (ENFLONSIA: 2.3%; placebo: 1.9%). Participants were monitored for serious adverse events (SAEs) through the duration of their participation for up to 365 days post-dose. Most (≥97%) of the adverse reactions were toxicity grade 1 (mild) or grade 2 (moderate).
The SMART trial (MK-1654-007) (NCT04938830) was a Phase 3, randomized, partially-blind, palivizumab-controlled, multi-site trial to evaluate the safety and efficacy of ENFLONSIA in infants at increased risk of severe RSV disease, including early (<29 weeks GA) or moderate preterm infants (≥29 to ≤35 weeks GA) and infants with chronic lung disease of prematurity or congenital heart disease of any GA. Participants were randomized 1:1 to receive ENFLONSIA (N=446) or palivizumab (N=450) by IM injection.
Among infants at increased risk of severe RSV disease and entering their first RSV season, the trial demonstrated that the safety profile of ENFLONSIA was generally comparable to palivizumab and consistent with the safety profile of ENFLONSIA in infants in the CLEVER trial. The efficacy of ENFLONSIA in infants at increased risk for severe RSV disease was established by extrapolation of efficacy of ENFLONSIA from the CLEVER trial to the SMART trial based on similar pharmacokinetic exposure. The incidence rates of RSV-associated MALRI requiring ≥1 indicator of LRI or severity and RSV-associated hospitalization were generally comparable between ENFLONSIA (3.6%, 95% CI: 2.0, 6.0 and 1.3%, 95% CI: 0.4, 2.9, respectively) and palivizumab (2.9%, 95% CI: 1.5, 5.2 and 1.5%, 95% CI: 0.5, 3.2, respectively) through Day 150 (5 months).
In clinical trials, when ENFLONSIA was given concomitantly with routine childhood vaccines, the safety profile of the co-administered regimen was generally comparable to the safety profile when ENFLONSIA and childhood vaccines were administered alone.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
Please see Prescribing Information for ENFLONSIA (clesrovimab-cfor) at https://www.merck.com/product/usa/pi_circulars/e/enflonsia / enflonsia_pi.pdf and Patient Information/Medication Guide for ENFLONSIA at https://www.merck.com/product/usa/pi_circulars/e/enflonsia / enflonsia_ppi.pdf.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Merck's Cholesterol Medication Achieves Primary Endpoint in Two Trials
Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials. A close-up of a person's hand holding a bottle of pharmaceuticals. The medication is being studied as a potential treatment for hyperlipidemia, a condition marked by high levels of fat in the bloodstream. According to the company, enlicitide led to significant reductions in LDL-C, or "bad" cholesterol, in patients with existing heart disease or those at risk of developing it. Merck & Co., Inc. (NYSE:MRK) is a global healthcare organization focused on providing innovative health solutions through its medicines, vaccines, biologic therapies, and animal health products. The stock has surged by over 1% in the past month. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Merck's Cholesterol Medication Achieves Primary Endpoint in Two Trials
Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials. A close-up of a person's hand holding a bottle of pharmaceuticals. The medication is being studied as a potential treatment for hyperlipidemia, a condition marked by high levels of fat in the bloodstream. According to the company, enlicitide led to significant reductions in LDL-C, or "bad" cholesterol, in patients with existing heart disease or those at risk of developing it. Merck & Co., Inc. (NYSE:MRK) is a global healthcare organization focused on providing innovative health solutions through its medicines, vaccines, biologic therapies, and animal health products. The stock has surged by over 1% in the past month. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.


Newsweek
3 hours ago
- Newsweek
Inside Hospitals' Digital Command Centers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. During the winter of 2023, staff at Children's Mercy Kansas City were waiting for the "surge": a dreaded period when viral illnesses like influenza and RSV abound, leading to an increase in hospital admissions. But as the winter bled into 2024, it became clear that something had changed. Children were still getting sick and requiring advanced medical care. However, staff at Children's Mercy weren't "feeling the angst" like they had in years past, according to Dr. Jennifer Watts, the hospital's associate chief medical officer of acute care and inpatient operations. The difference, Watts said, came from technology. That was the hospital's first year using GE HealthCare's Command Center software, a product that allows it to digitally monitor care delivery and track patients' progress throughout their stay. It's like the "NASA" control hub for the health system, Watts told Newsweek. During the first winter partnering with GE, Children's Mercy staff began asking, "Is the surge here?" "They just didn't feel it," Watts said. "We were able to prepare. We were able to have [sufficient] staff present. We got rid of the scramble that typically occurs when you don't prepare for things." Hospital staff inside Children's Mercy Kansas City's Patient Progression Hub, which uses GE Healthcare Command Center technology to paint a real-time picture of hospital happenings. Hospital staff inside Children's Mercy Kansas City's Patient Progression Hub, which uses GE Healthcare Command Center technology to paint a real-time picture of hospital happenings. Children's Mercy Kansas City Patient Progression Hub Children's Mercy is one of 300 hospitals around the world that use GE's Command Center technology. As hospitals across the U.S. face rising demand for their services—driven, in part, by sicker patients and an aging population—many are turning to these digital "command centers" to improve operational efficiency and polish the patient experience. Before developing a Patient Progression Hub, driven by GE's tech, Children's Mercy was still dealing with inefficient and outdated processes, according to Watts. Different departments were playing "phone tag" with one another to move patients through the hospital. Information was not centralized, and it was common to see staff with packets of papers in front of them, pinning memos on bulletin boards and communicating with fax machines. Within seven months of implementing the Command Center technology, the hospital saw an 86 percent reduction in admission delays and cut avoidable bed days by 24 percent—creating capacity for 300 more medical-surgical patients without expanding its facility. The tech sits atop hospitals' preexisting systems, like staffing platforms and electronic health records (EHRs), to generate a comprehensive, real-time picture of the hospital's caseload and available resources. "The software really helps connect the strategy to the day-to-day operations," Bree Bush, general manager of GE's Command Center, told Newsweek. Kristie Barazsu is the president and COO of Duke Health Lake Norman Hospital in Mooresville, North Carolina, and oversees patient flow for Duke Health, which stood up Command Center in 2019. During COVID-19, the health system could use the technology to understand where positive patients were located and deploy personal protective equipment (PPE) from its logistics center. Command Center also utilizes predictive analytics to help hospitals plan for the future. Duke uses it to forecast the area's census, analyzing overall demand by unit, patient population and information has informed the health system's staffing plan, allowing it to reduce reliance on costly, temporary travel labor—and reducing labor expenses by approximately $40 million to date, according to Barazsu. Rather than viewing the hospitals within Duke's system as independent entities, a tech Command Center has enabled leadership to get the full picture, she added. The system can now move patients from one hospital to another more quickly, allowing it to free up bed space and accept more transfers from other health systems. "We're not relying on word of mouth or pagers or systems that don't work well," Barazsu told Newsweek. "There's one source of truth." Staff coordinate care inside UMass Memorial Health's new Digital Hub. Staff coordinate care inside UMass Memorial Health's new Digital Hub. UMass Memorial Health While some health systems are partnering with a tech provider like GE, others are developing internal solutions to manage demand—and to keep tabs on a broadening menu of digital services. UMass Memorial Health has been on the forefront of the digital revolution, according to Dr. Eric Alper, its vice president, chief quality and chief clinical informatics officer. The health system was an early adopter of electronic intensive care unit (eICU) technology, which allows ICU staff to virtually connect with a critical care physician on overnight shifts. But a lot has changed since the advent of eICU tech about two decades ago, Alper told Newsweek. UMass Memorial used to run the service from a basement. Eventually it was supporting 150 critical care beds across the enterprise, and it was time for an upgrade. The health system recently stood up a new Digital Hub, a 20,000-square-foot home for its eICU services, and several other virtual programs, including interpreter services, remote video monitoring, mobile integrated health, "ED at Home," primary care and the Transfer and Access Center, which coordinates the comings and goings of patients across UMass Memorial hospitals. It might sound paradoxical to move virtual services to a physical location, but centralizing these operations has allowed for better communication, according to Alper, "We're collaborating more effectively by being in the same space, and that's allowing us to reduce some of the silos." An urgent care provider conducts a virtual visit from Sanford Health's Virtual Care Center. An urgent care provider conducts a virtual visit from Sanford Health's Virtual Care Center. Sanford Health Across the country in Sioux Falls, South Dakota, leaders at Sanford Health shared similar goals. The system stood up its own 60,000-square-foot Virtual Care Center in November, funded by a $350 million gift from its namesake Denny Sanford. In April, Newsweek followed up on the initiative with Dr. Dave Newman, Sanford's chief medical officer of virtual care. "One of the biggest things that the Virtual Care Center has done for Sanford is it emphasized the validity of virtual care and digital health," Newman told Newsweek. "The investment in the center and the space has shown that it's permanent, that this is what we're doing to help our patients, not just today or tomorrow but also 20 years from now." For Watts at Children's Mercy Kansas City, one incident stands out as a testament to the tech Command Center's importance. Anytime there is a mass casualty event, nearby hospitals need to prepare 20 percent of their beds to accept new patients. That's a challenge for most hospitals, given their daily capacity constraints—but when a shooter opened fire on the Kansas City Chiefs' Super Bowl parade in February 2024, Children's Mercy was able to respond. "This occurred a mile from our children's hospital, and we had no idea up front how many victims we would be receiving," Watts said, "but we were able to use the results of [Command Center predictive] modeling to get us to a point where, yes, we could take 20 percent of our beds and treat all of the victims that may be coming through our doors." She's excited to see hospitals' virtual command centers and digital services grow, saying, "I think we have opened the Pandora's box here."